COMP Flash | TEVA’s € 462.6 million fine over patent misuse & harming rivals’ reputation

The European Commission fines Teva €462.6 million over misuse of the patent system and disparagement to delay rival multiple sclerosis medicine.

Today's decision concludes that Teva's abuses were complementary and together amounted to a single and continuous infringement of EU law.

This is the first time the Commission has imposed a fine in relation to these two types of practices.

Here explained by Anna Vernet, Head of Unit for Antitrust: Pharma and Health Services at DG Competition.

#EUAntitrust #EUCompetition #Pharma #Teva